Target intelligence / Profile preview

Lachesis muta venom serine protease (LmSVSP)

Target
LmSVSP
Molecular classification
Enzyme, Serine protease, Snake venom serine protease (SVSP)
01

Overview

Lachesis muta venom serine proteases (LmSVSPs) are a critical class of enzymes found in the venom of the South American Bushmaster snake, Lachesis muta. These enzymes function primarily by disrupting the host's hemostatic system, frequently acting as thrombin-like enzymes that cleave fibrinogen into unstable fibrin clots. This activity leads to the rapid depletion of circulating fibrinogen, resulting in a clinical state of consumptive coagulopathy and severe systemic bleeding (Torres-Huaco et al., 2013). Beyond their toxicological role, LmSVSPs are studied for their potential therapeutic applications as defibrinogenating agents to treat or prevent thrombotic disorders. They are the primary targets for neutralization by specific and polyvalent antivenoms during the clinical management of snakebite (NCBI, 2023). Understanding the molecular structure and substrate specificity of these proteases is essential for improving antivenom efficacy and for the development of novel anticoagulants.

Other names
Bushmaster snake venom serine proteaseLachesis muta thrombin-like enzymeLm-TLEFibrinogenolytic enzymeGyroxin-like enzyme
02

Mechanism of action

LmSVSPs primarily act as thrombin-like enzymes that cleave fibrinogen (typically the alpha or beta chains) to produce fibrin monomers. Unlike physiological thrombin, these enzymes often do not activate Factor XIII, resulting in the formation of weak, non-cross-linked fibrin clots that are rapidly degraded by the body's fibrinolytic system, leading to systemic defibrinogenation and coagulopathy (Diniz-Sousa et al., 2020; UniProt P81131).

03

Biological functions

ProteolysisFibrinogen cleavageHemostasis regulationPlatelet aggregation modulationBlood coagulation
04

Disease associations

Snakebite envenomationConsumptive coagulopathyHemorrhageThrombosis
05

Safety considerations

Severe systemic hemorrhageHypofibrinogenemiaAnaphylaxis (associated with antivenom treatment)Resistance to heparin therapy
06

Interacting drugs

Lachesis muta antivenom

4 more in the full profile.

07

Biomarkers

Fibrinogen levelsProthrombin time (PT)Activated partial thromboplastin time (aPTT)D-dimerFibrin degradation products (FDPs)

Beyond the preview

Go deeper on Lachesis muta venom serine protease (LmSVSP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lachesis muta venom serine protease (LmSVSP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call